Neuronetics, Inc. (STIM) Revenue History
Annual and quarterly revenue from 2016 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
STIM Revenue Growth
Revenue Breakdown (FY 2025)
STIM's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
STIM Revenue Analysis (2016–2025)
As of May 7, 2026, Neuronetics, Inc. (STIM) generated trailing twelve-month (TTM) revenue of $151.6 million, reflecting solid growth of +7.8% year-over-year. The most recent quarter (Q1 2026) recorded $34.5 million in revenue, down 17.5% sequentially.
Looking at the longer-term picture, STIM's 5-year compound annual growth rate (CAGR) stands at +24.8%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $149.2 million in 2025, representing a new all-time high.
Revenue diversification analysis shows STIM's business is primarily driven by Clinical Services Segment (58%), and Medical Device Segment (42%). With over half of revenue concentrated in Clinical Services Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ELMD (+15.5% YoY), NVCR (+8.5% YoY), and ABSI (-38.2% YoY), STIM has underperformed the peer group in terms of revenue growth. Compare STIM vs ELMD →
STIM Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| STIMCurrent | $152M | +7.8% | +24.8% | -21.1% | |
 ELMD | $64M | +15.5% | +14.5% | 15.1% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 ABSI | $3M | -38.2% | -10.1% | -4454.2% | |
 LIVN | $1.4B | +12.4% | +8.2% | 14.4% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% |
STIM Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $149.2M | +99.2% | $72.3M | 48.5% | $-31,436,000 | -21.1% |
| 2024 | $74.9M | +5.0% | $54.2M | 72.3% | $-34,563,000 | -46.2% |
| 2023 | $71.3M | +9.4% | $51.7M | 72.5% | $-30,554,000 | -42.8% |
| 2022 | $65.2M | +17.9% | $49.7M | 76.3% | $-35,111,000 | -53.8% |
| 2021 | $55.3M | +12.3% | $43.7M | 78.9% | $-27,564,000 | -49.8% |
| 2020 | $49.2M | -21.4% | $37.7M | 76.5% | $-22,309,000 | -45.3% |
| 2019 | $62.7M | +18.7% | $47.3M | 75.4% | $-26,930,000 | -43.0% |
| 2018 | $52.8M | +30.5% | $40.3M | 76.4% | $-19,834,000 | -37.6% |
| 2017 | $40.4M | +18.1% | $30.8M | 76.2% | $-13,608,000 | -33.7% |
| 2016 | $34.2M | - | $27.6M | 80.7% | $-9,337,000 | -27.3% |
See STIM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs STIM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare STIM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSTIM — Frequently Asked Questions
Quick answers to the most common questions about buying STIM stock.
Is STIM's revenue growth accelerating or slowing?
STIM maintains +7.8% revenue growth, in line with its 5-year CAGR of +24.8%. TTM revenue stands at $152M. Growth rate remains consistent with historical average.
What is STIM's long-term revenue growth rate?
Neuronetics, Inc.'s 5-year revenue CAGR of +24.8% reflects the sustained expansion pattern. Current YoY growth of +7.8% is near this long-term average.
How is STIM's revenue distributed by segment?
STIM reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2025 are available for download. Segment mix reveals concentration and diversification trends.